Abstract

Ferroptosis has emerged as a new type of cell death in different pathological conditions, including neurological and kidney diseases and, especially, in different types of cancer. The hallmark of this regulated cell death is the presence of iron-driven lipid peroxidation; the activation of key genes related to this process such as glutathione peroxidase-4 (gpx4), acyl-CoA synthetase long-chain family member-4 (acsl4), carbonyl reductase [NADPH] 3 (cbr3), and prostaglandin peroxidase synthase-2 (ptgs2); and morphological changes including shrunken and electron-dense mitochondria. Iron overload in the liver has long been recognized as both a major trigger of liver damage in different diseases, and it is also associated with liver fibrosis. New evidence suggests that ferroptosis might be a novel type of non-apoptotic cell death in several liver diseases including non-alcoholic steatohepatitis (NASH), alcoholic liver disease (ALD), drug-induced liver injury (DILI), viral hepatitis, and hemochromatosis. The interaction between iron-related lipid peroxidation, cellular stress signals, and antioxidant systems plays a pivotal role in the development of this novel type of cell death. In addition, integrated responses from lipidic mediators together with free iron from iron-containing enzymes are essential to understanding this process. The presence of ferroptosis and the exact mechanisms leading to this non-apoptotic type of cell death in the liver remain scarcely elucidated. Recognizing ferroptosis as a novel type of cell death in the liver could lead to the understanding of the complex interaction between different types of cell death, their role in progression of liver fibrosis, the development of new biomarkers, as well as the use of modulators of ferroptosis, allowing improved theranostic approaches in the clinic.

Highlights

  • In the liver, the presence of hepatocyte death is reflected in the levels of serum transaminases, which are the most widely used markers of hepatic function [1]

  • The disruption of this pathway has been linked to various liver diseases including Non-Alcoholic Fatty Liver Disease (NAFLD), hepatocellular carcinoma (HCC), and chronic viral hepatitis, among others, [29] and autophagy has been mainly described as a “recycling” mechanism, there is evidence showing that autophagy could be associated to liver cell death

  • A more detailed analysis of the mechanisms of cell death would be recommended, the findings in this study suggest that autophagy could elicit cell death under some specific circumstances [24]

Read more

Summary

Introduction

The presence of hepatocyte death is reflected in the levels of serum transaminases, which are the most widely used markers of hepatic function [1] These markers have prognostic value in a wide range of chronic liver diseases, often involving persistent inflammation of any underlying cause, such as hepatitis C virus infection (HCV), alcoholic liver disease (ALD), non-alcoholic steatohepatitis (NASH), drug-induced liver injury (DILI), and hepatocellular carcinoma (HCC) [2,3,4]. Distinct forms of hepatocyte cell death include apoptosis (a typical form of PCD), necrosis, pyroptosis, necroptosis, and autophagy The differences between these modes of liver cell death include distinct changes in the nucleus, cytoplasm, and other organelles such as lysosomes. The clinical implications of recognizing this type of cell death are described

General Mechanisms of Liver Cell Death
Apoptosis
Necrosis and Necroptosis
Autophagy
Pyroptosis
Iron Metabolism
Ferroptosis
The Role of Lipids in Ferroptosis
Keap1-Nrf2 System
Interaction between Iron and Oxidative Stress
Proposed Biomarkers of Ferroptotic Cell Death
10. Ferroptosis and Liver Disease
10.1. Ferroptosis in Metabolic Liver Diseases
10.3. Ferroptosis and Viral Hepatitis
11. Experimental Models of Iron Overload and Liver Damage
12. Clinical Implications for the Study of Ferroptosis
13. Pharmacological Modulation of Ferroptosis
Findings
14. Conclusions and Future Perspectives
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call